- Home
- CKPT vs KRMD Comparison
CKPT vs KRMD Comparison
Compare CKPT & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- KRMD
- Stock Information
- Founded
- CKPT 2014
- KRMD 1980
- Country
- CKPT United States
- KRMD United States
- Employees
- CKPT N/A
- KRMD N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- KRMD Medical/Dental Instruments
- Sector
- CKPT Health Care
- KRMD Health Care
- Exchange
- CKPT Nasdaq
- KRMD Nasdaq
- Market Cap
- CKPT 172.4M
- KRMD 187.5M
- IPO Year
- CKPT 2017
- KRMD N/A
- Fundamental
- Price
- CKPT $3.13
- KRMD $3.71
- Analyst Decision
- CKPT Strong Buy
- KRMD Strong Buy
- Analyst Count
- CKPT 3
- KRMD 5
- Target Price
- CKPT $12.00
- KRMD $4.70
- AVG Volume (30 Days)
- CKPT 753.4K
- KRMD 283.8K
- Earning Date
- CKPT 03-21-2025
- KRMD 03-12-2025
- Dividend Yield
- CKPT N/A
- KRMD N/A
- EPS Growth
- CKPT N/A
- KRMD N/A
- EPS
- CKPT N/A
- KRMD N/A
- Revenue
- CKPT $47,000.00
- KRMD $31,993,796.00
- Revenue This Year
- CKPT N/A
- KRMD $20.53
- Revenue Next Year
- CKPT $300,658.78
- KRMD $13.94
- P/E Ratio
- CKPT N/A
- KRMD N/A
- Revenue Growth
- CKPT N/A
- KRMD 11.57
- 52 Week Low
- CKPT $1.38
- KRMD $2.01
- 52 Week High
- CKPT $4.50
- KRMD $5.05
- Technical
- Relative Strength Index (RSI)
- CKPT 46.36
- KRMD 34.58
- Support Level
- CKPT $3.10
- KRMD $4.55
- Resistance Level
- CKPT $3.43
- KRMD $4.83
- Average True Range (ATR)
- CKPT 0.26
- KRMD 0.26
- MACD
- CKPT 0.00
- KRMD -0.12
- Stochastic Oscillator
- CKPT 33.03
- KRMD 2.19
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).